Navigation Links
China Medical Technologies Announces the Use of its HER-2 FISH Probe in a Cancer Targeted Therapy Research Project Sponsored by the Chinese Ministry of Health
Date:7/15/2010

BEIJING, July 15 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that its HER-2 FISH probe has been chosen to be used in a research project focusing on cancer targeted therapy standardization, as well as early cancer detection and treatment, which is sponsored by the Chinese Ministry of Health. One of the subjects of this research project is to standardize the process and procedures for the use of FISH technology to detect HER-2 gene amplification in breast cancer and stomach cancer patients to guide the use of Herceptin (the "HER-2 Study"). The Company is the supplier of HER-2 FISH probe for the HER-2 Study.

Immunohistochemistry used to be the traditional diagnostic method in detecting HER-2 gene amplification in China, but it has false positive and false negative results. The HER-2 Study is the first study in China to include FISH technology as the gold standard in HER-2 gene amplification detection. The Company believes that the results of the HER-2 Study may contribute to more widespread use of its HER-2 FISH probe in the companion diagnostic test market in China for guiding treatment for breast cancer and stomach cancer. According to the Chinese Central Government's Official Web Portal, about 200,000 new cases of breast cancer and 400,000 new cases of stomach cancer are diagnosed in China each year.

"We believe that our selection as the supplier of HER-2 FISH probe in the HER-2 Study by the top ranking cancer research institute demonstrates the good quality of our HER-2 FISH probe," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company.

The HER-2 Study is led by the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences with Dr. Yuankai Shi as the principal investigator.

About China Medical Technologies, Inc.

China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com .

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, including the risk that the results of the HER-2 Study will not lead to increased use of the Company's HER-2 FISH probe. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

    For more information, please contact:

     Winnie Yam
     Phone: +852-2511-9808
     Email: IR@chinameditech.com


'/>"/>
SOURCE China Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MarketsandMarkets: Patient Monitoring Devices Markets in Brazil, Russia, India and China Worth $2,992 Million by 2015
2. Renhuang Showcases its All Natural Products at 45th China National New and Special Drugs Fair
3. China Medicine Announces Stock Repurchase Plan
4. Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
5. New Report Patient Monitoring Emerging Markets (BRIC - Brazil, Russia, India and China) 2010 - 2014 Published by MarketsandMarkets
6. China-Biotics, Inc. Announces US$20 million Share Buyback Program
7. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
8. Weikang Bio-Technology to Present at Global Hunter 2010 China Conference on July 13, 2010
9. China Medical Technologies to Announce Results for the First Fiscal Quarter Ended June 30, 2010 on August 16, 2010
10. Samplify Expands Global Presence; Opens China Office
11. China PharmaHub Corp. Enters Into Definitive Agreement for Humanized Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an ... that it has acquired exclusive worldwide rights to ... innovative HDAC inhibitor targeting hematological and solid tumors. ... Phase 1 and 2 clinical trials of Abexinostat ... have already been completed, demonstrating that Abexinostat ...
(Date:2/23/2017)... Feb. 23, 2017  Genesis Healthcare Services has merged ... was made by Bill Monast , President and ... and Nathan Feltman , executives with Home Health ... LLC. This acquisition helps Hospice Cloud ... technology enabled durable medical equipment (DME) solutions for the ...
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have the ability ... total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass ... , With ProGlass Prism users are given the tools and effects to generate ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management Association ... marketing programs at the annual Building Better Radiology Marketing Programs conference, held ... in Fort Worth, Texas. Nine awards are given out in five categories. They are:, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... of Justice jointly issued a letter to withdraw previous guidance issued ... their gender identity. The guidance issued in May 2016 by the Obama Administration ...
(Date:2/23/2017)... Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... first two episodes of WE TV’s “Mama June: From Not to Hot,” which will ... TV notable, “Mama” June Shannon, known to millions from the 2012 reality television series, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena Dental, a comprehensive ... was named a 2017 Top Patient Rated Henderson Dentist by Find Local ... recognizes local physicians and dentists who have earned high ratings and superior patient reviews ...
Breaking Medicine News(10 mins):